PureTech Health PLC

PureTech Health PLC

  • Price (USD)4.24
  • Today's Change0.44 / 11.58%
  • Shares traded30.00k
  • 1 Year change92.73%
  • Beta0.8244
Data delayed at least 15 minutes, as of Nov 19 2019 20:57 GMT.
More ▼

Profile data is unavailable for this security.

About the company

PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets. This segment includes subsidiary companies, which include Vedanta Biosciences, Inc., Gelesis, Inc., Akili Interactive Lab, Inc., Tal Medical, Inc., Karuna Pharmaceuticals, Inc., Entrega Inc. and Follica Incorporated. Businesses in the project phase businesses segment are those whose activities are focused on financing, sourcing and creating new product candidates and newly created businesses whose technologies are in the process of validation. This segment includes subsidiary companies, which include The Sync Project Inc., Sonde Health, Inc., Commense Inc., Alivio Therapeutics, Inc., Vor Biopharma Inc., Enlight Biosciences, LLC, Mandara Sciences, LLC and Knode Inc.

  • Revenue in GBP (TTM)15.60m
  • Net income in GBP-5.66m
  • Incorporated2015
  • Employees225.00
  • Location
    PureTech Health PLC501 Boylston St Ste 6102BOSTON 02116-3769United StatesUSA
  • Phone+1 (617) 482-2333
  • Fax+1 (617) 482-3337
  • Websitehttp://puretechhealth.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PRTC:LSE since
Ariya Therapeutics IncDeal completed02 Oct 201902 Oct 2019Deal completed12.94%666.98m
Data delayed at least 20 minutes, as of Nov 20 2019 14:14 GMT.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.